Accelerated FEV

Accelerated lung function decline has been associated with increased risk of cardiovascular disease (CVD) in a general population, but little is known about this association in chronic obstructive pulmonary disease (COPD). We investigated the association between accelerated lung function decline and CVD outcomes and mortality in a primary care COPD population.COPD patients without a history of CVD were identified in the Clinical Practice Research Datalink (CPRD)-GOLD primary care dataset (n=36 382). Accelerated decline in forced expiratory volume in 1 s (FEV

Informations de copyright

Copyright ©ERS 2021.

Déclaration de conflit d'intérêts

Conflict of interest: H.R. Whittaker reports grants from GSK, AstraZeneca and BI, outside the submitted work. Conflict of interest: C. Bloom reports funding from AstraZeneca, Chiesi and Asthma UK, outside the submitted work. Conflict of interest: A. Morgan has nothing to disclose. Conflict of interest: D. Jarvis reports grants from the European Union and Cystic Fibrosis Trust, outside the submitted work. Conflict of interest: S.J. Kiddle reports grants from the Medical Research Council (grant number MR/P021573/1), during the conduct of the study; and personal fees from Roche Diagnostics and DIADEM, outside the submitted work. Conflict of interest: J.K. Quint reports grants from the British Lung Foundation, during the conduct of the study; grants and personal fees from AstraZeneca, BI, Bayer and GSK, and grants from Asthma UK, the Medical Research Council and Chiesi, outside the submitted work.